Objective
To determine whether a chemokine receptor type 2 antagonist, DMX-200 (repagermanium), in combination with an angiotensin receptor blocker, candesartan, improves clinical outcomes in people with COVID-19.
Design
Prospective, multicentre, double-blind, placebo-controlled trial.
Setting
Ten acute care hospitals in India.
Participants
Adults